News 17.05.2021 Schlieren (Zurich), Switzerland, May 17, 2021 – Kuros Biosciences (“Kuros”), a leader in next generation bone graft technologies, today announced it will receive a milestone payment of $4 million from Checkmate Pharmaceuticals, Inc. related to dosing of the first patient in a Phase 2 trial of vidutolimod (CMP-001) in combination...
News 06.05.2021 Zurich-Schlieren, Switzerland, May 06, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced results from parallel laboratory studies conducted in collaboration with academic and government partners in Switzerland and the United States. The...
News 05.05.2021 Schlieren (Zurich), Switzerland, May 5, 2021 – Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled ‘Pharmaceutical Formulation for Use in Spinal Fusion’. This patent claims certain matrix materials in...
News 04.05.2021 Zurich-Schlieren, Switzerland and Naples, Italy, May 04, 2021 – The University of Naples Federico II, Italy and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer patient management, will be clinically evaluated and made routinely available in Italy. ”Proclarix® is an innovative decision...
News 04.05.2021 Zurich-Schlieren, Switzerland, May 04, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. “Molecular Partners continues to grow and expand the reach of...